Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

Blood

Volumn 123, Issue 14, 2014, Pages 2157-2160

  Guglielmelli, Paola ^a   Biamonte, Flavia ^a   Rotunno, Giada ^a   Artusi, Valentina ^b   Artuso, Lucia ^b   Bernardis, Isabella ^b   Tenedini, Elena ^b   Pieri, Lisa ^a   Paoli, Chiara ^a   Mannarelli, Carmela ^a   Fjerza, Rajmonda ^a   Rumi, Elisa ^c   Stalbovskaya, Viktoriya ^d   Squires, Matthew ^d   Cazzola, Mario ^c   Manfredini, Rossella ^b   Harrison, Claire ^e   Tagliafico, Enrico ^b   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; RUXOLITINIB; STAT PROTEIN; TRANSCRIPTION FACTOR EZH2;

ANEMIA; ARTICLE; ASXL1 GENE; FOLLOW UP; GENE; GENE FREQUENCY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MORTALITY; MUTATIONAL ANALYSIS; MYELOFIBROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SPLEEN SIZE; SPLENOMEGALY; SRSF2 GENE; SURVIVAL; THROMBOCYTOPENIA;

DNA MUTATIONAL ANALYSIS; HUMANS; ISOCITRATE DEHYDROGENASE; JANUS KINASE 1; JANUS KINASE 2; MUTATION; NUCLEAR PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; REPRESSOR PROTEINS; RIBONUCLEOPROTEINS; TREATMENT OUTCOME;

EID: 84899056972     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-536557     Document Type: Article

References (22)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-191.
2. Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30(24):2981-2987.
3. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401-408.
4. Harrison CN, Mesa RA, Kiladjian JJ, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013;162(2):229-239.
5. Kröger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia. 2008;22(3):474-486. (Pubitemid 351386717)
6. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
7. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
8. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
9. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008;22(10):1813-1817.
10. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379- 2390.
11. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
12. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons [published online ahead of print January 9, 2014]. Leukemia. doi:10.1038/leu.2014.3.
13. Anand S, Stedham F, Gudgin E, et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood. 2011;118(6):1610-1621.
14. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-1735.
15. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
16. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011;118(19):5227-5234.
17. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012;120(20):4168-4171.
18. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869.
19. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
20. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
21. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-1871.
22. Cervantes F, Vannucchi AM, Kiladjian J-J, et al; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.